Citigroup Inc Inhibrx, Inc. Transaction History

Citigroup Inc

$150 Billion
Q1 2024

A detailed history of Citigroup Inc transactions in Inhibrx, Inc. stock. As of the latest transaction made, Citigroup Inc holds 331,302 shares of INBX stock, worth $4.69 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

331,302

Previous 44,690 641.33%

Holding current value

$4.69 Million

Previous $1.7 Million 582.1%

% of portfolio

0.01%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$32.76 - $39.56 $9.39 Million - $11.3 Million	286,612 Added 641.33%	331,302 $11.6 Million
Q4 2023 Feb 09, 2024	SELL	$14.5 - $38.0 $66,033 - $173,052	-4,554 Reduced 9.25%	44,690 $1.7 Million
Q3 2023 Nov 09, 2023	BUY	$15.75 - $26.31 $25,373 - $42,385	1,611 Added 3.38%	49,244 $903,000
Q2 2023 Aug 10, 2023	SELL	$16.96 - $27.82 $1.3 Million - $2.13 Million	-76,702 Reduced 61.69%	47,633 $1.24 Million
Q1 2023 May 11, 2023	BUY	$18.45 - $27.14 $697,815 - $1.03 Million	37,822 Added 43.72%	124,335 $2.35 Million

Q4 2022 Feb 09, 2023	SELL	$20.18 - $33.33 $705,250 - $1.16 Million	-34,948 Reduced 28.77%	86,513 $2.13 Million
Q3 2022 Nov 10, 2022	BUY	$11.58 - $24.73 $1.37 Million - $2.93 Million	118,361 Added 3818.1%	121,461 $2.18 Million
Q2 2022 Aug 10, 2022	SELL	$8.52 - $25.26 $117,797 - $349,244	-13,826 Reduced 81.68%	3,100 $36,000
Q1 2022 May 12, 2022	SELL	$19.89 - $43.18 $401,360 - $871,329	-20,179 Reduced 54.38%	16,926 $377,000
Q4 2021 Feb 10, 2022	BUY	$26.75 - $46.02 $902,090 - $1.55 Million	33,723 Added 997.13%	37,105 $1.62 Million
Q3 2021 Nov 10, 2021	BUY	$25.18 - $37.81 $85,158 - $127,873	3,382 New	3,382 $113,000

Others Institutions Holding INBX

# of Institutions

132

Shares Held

35.5M

Call Options Held

64.8K

Put Options Held

91.3K

View Full List

About Inhibrx, Inc.

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $553M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

More about INBX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account